scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Acquired by BNP Paribas Financial Markets

BNP Paribas Financial Markets increased its holdings in shares of scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) by 1,393.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 85,900 shares of the company's stock after purchasing an additional 80,147 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.17% of scPharmaceuticals worth $304,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Legato Capital Management LLC purchased a new stake in shares of scPharmaceuticals during the 4th quarter worth approximately $37,000. China Universal Asset Management Co. Ltd. purchased a new stake in scPharmaceuticals in the fourth quarter valued at $38,000. Price T Rowe Associates Inc. MD acquired a new position in scPharmaceuticals in the fourth quarter valued at $54,000. Wells Fargo & Company MN boosted its stake in scPharmaceuticals by 110.5% in the fourth quarter. Wells Fargo & Company MN now owns 18,407 shares of the company's stock valued at $65,000 after acquiring an additional 9,663 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in shares of scPharmaceuticals during the fourth quarter worth about $66,000. 89.52% of the stock is owned by institutional investors and hedge funds.

scPharmaceuticals Price Performance

Shares of NASDAQ SCPH traded down $0.01 during trading on Friday, reaching $3.54. The company had a trading volume of 288,816 shares, compared to its average volume of 366,966. The company has a current ratio of 8.08, a quick ratio of 6.89 and a debt-to-equity ratio of 1.66. scPharmaceuticals Inc. has a twelve month low of $1.94 and a twelve month high of $5.65. The stock has a 50-day moving average price of $2.67 and a two-hundred day moving average price of $3.13. The stock has a market capitalization of $186.88 million, a PE ratio of -1.86 and a beta of 0.17.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.06). scPharmaceuticals had a negative net margin of 264.60% and a negative return on equity of 244.93%. The firm had revenue of $11.75 million during the quarter, compared to analyst estimates of $11.63 million. As a group, sell-side analysts predict that scPharmaceuticals Inc. will post -1.53 earnings per share for the current year.

Analyst Upgrades and Downgrades

SCPH has been the subject of a number of research reports. Maxim Group reduced their target price on shares of scPharmaceuticals from $20.00 to $12.00 and set a "buy" rating for the company in a report on Thursday, March 20th. HC Wainwright reiterated a "buy" rating and set a $18.00 target price on shares of scPharmaceuticals in a research report on Thursday, March 20th.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.